China State Institute of Pharmaceutical Industry (CSIPI), where her research focused on small-molecule drug design and synthesis, with particular interests in bioactive compounds. She started her PhD at Helmholtz

• charlotte.odonnell@helmholtz-hips.de
• +49 68198806-2061

working on the synthesis of novel anti-infectives and the application of protein-templated techniques in drug discovery.

• amayajaykumar.agrawal@helmholtz-hips.de
• +4917675472860

Bioengineering from TU Dresden, Germany. Following his Master's degree, he started as a PhD student in Drug Bioinformatics group in November, 2021. His research focuses on using explainable Artificial Intelligence

• guangyi.chen@helmholtz-hips.de

Master’s degree in Bioinformatics from Saarland University, Germany. He started as a PhD student in Drug Bioinformatics group in HIPS from 2022. His research aims to develop a novel therapeutic approach

• mayukh.bhattacharyya@helmholtz-hips.de

LTM-produced antibiotics, as well as potential effects on the microbiome, toxicity, immune response, and drug metabolism.

• angela.sester@helmholtz-hips.de
• +49-681-98806-5520

Dortmund University under Prof. Dr. Markus Nett, where she mainly investigated myxobacteria for new drug classes. As a postdoc at the TU Dresden with Prof. Dr. Tobias A. M. Gulder, the research focus shifted

• sidra.eisa@helmholtz-hips.de
• +49 6819 8806-2052

Later, she pursued her PhD at HIPS under the supervision of Prof. Anna Hirsch at the Department of Drug Design and Optimization, working on the synthesis of novel inhibitors targeting underexplored bacterial

• Xiaoqi.ji@helmholtz-hips.de
• +49 1520571388

research focuses on enzyme catalysis, natural product biosynthesis, and sustainable strategies for drug discovery.